[go: up one dir, main page]

WO1996035788A3 - Kunitz type protease inhibitors - Google Patents

Kunitz type protease inhibitors Download PDF

Info

Publication number
WO1996035788A3
WO1996035788A3 PCT/US1996/006384 US9606384W WO9635788A3 WO 1996035788 A3 WO1996035788 A3 WO 1996035788A3 US 9606384 W US9606384 W US 9606384W WO 9635788 A3 WO9635788 A3 WO 9635788A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogues
kpi
protease inhibitors
type protease
kunitz type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/006384
Other languages
French (fr)
Other versions
WO1996035788A2 (en
Inventor
Tyler R White
Deborah Damm
David D Lesikar
Kethleen Mcfadden
Brett L Garrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Priority to EP96920140A priority Critical patent/EP0827539A2/en
Priority to JP8534170A priority patent/JPH11504938A/en
Priority to AU58540/96A priority patent/AU5854096A/en
Publication of WO1996035788A2 publication Critical patent/WO1996035788A2/en
Publication of WO1996035788A3 publication Critical patent/WO1996035788A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Analogues of the Kunitz Protease Inhibitor (KPI) domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, Xa, XIa and XIIa. Pharmaceutical compositions containing the KPI analogues, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these analogues and systems for expression of the peptides of the invention are provided.
PCT/US1996/006384 1995-05-08 1996-05-08 Kunitz type protease inhibitors Ceased WO1996035788A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP96920140A EP0827539A2 (en) 1995-05-08 1996-05-08 Kunitz type protease inhibitors
JP8534170A JPH11504938A (en) 1995-05-08 1996-05-08 Kunitz-type protease inhibitor
AU58540/96A AU5854096A (en) 1995-05-08 1996-05-08 Kunitz type protease inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43655595A 1995-05-08 1995-05-08
US64373196A 1996-05-06 1996-05-06
US08/643,731 1996-05-06
US08/436,555 1996-05-06

Publications (2)

Publication Number Publication Date
WO1996035788A2 WO1996035788A2 (en) 1996-11-14
WO1996035788A3 true WO1996035788A3 (en) 1996-12-12

Family

ID=27031013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/006384 Ceased WO1996035788A2 (en) 1995-05-08 1996-05-08 Kunitz type protease inhibitors

Country Status (6)

Country Link
EP (1) EP0827539A2 (en)
JP (1) JPH11504938A (en)
KR (1) KR19990008458A (en)
AU (1) AU5854096A (en)
CA (1) CA2220497A1 (en)
WO (1) WO1996035788A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DK0891426T3 (en) 1996-03-11 2006-10-02 Bayer Corp The human beak
AU4207499A (en) * 1998-05-28 1999-12-13 Zymogenetics Inc. Kunitz domain polypeptide and materials and methods for making it
CA2330191A1 (en) * 1998-06-03 1999-12-09 Scios, Inc. Protease inhibitor peptides
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7902156B2 (en) 2005-02-18 2011-03-08 Angiochem Inc. Aprotinin polypeptides for transporting a compound across the blood-brain barrier
EP1907009A4 (en) 2005-07-15 2009-09-02 Angiochem Inc Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
EP2231702A1 (en) * 2007-12-21 2010-09-29 Ifxa A/s Protease inhibitor
BRPI0922689A2 (en) 2008-12-05 2018-11-06 Angiochem Inc. neurotensin conjugates or neurotensin analogs and uses thereof
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
HUE039605T2 (en) 2010-01-06 2019-01-28 Dyax Corp Plasma kallikrein binding proteins
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
US20180362616A1 (en) * 2015-12-10 2018-12-20 The National Institute for Biotechnology in the Negev Ltd. VARIANTS OF AMYLOID beta-PROTEIN PRECURSOR INHIBITOR DOMAIN
IL259691B2 (en) 2015-12-11 2024-08-01 Dyax Corp Plasma kallikrein inhibitors and their uses in the treatment of hereditary angioedema attack
CN110051830A (en) * 2019-03-14 2019-07-26 苏州新凝生物医药科技有限公司 A kind of protease nexin II KPI protein mutant application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393431A1 (en) * 1989-04-18 1990-10-24 Bayer Ag Homologues of Alzheimer protease inhibitor prepared genetechnologically, host-strains and expression vectors for their preparation and use as a medicament
WO1993014120A1 (en) * 1992-01-07 1993-07-22 Novo Nordisk A/S A human kunitz-type protease inhibitor variant
WO1993014119A1 (en) * 1992-01-07 1993-07-22 Novo Nordisk A/S Human kunitz-type protease inhibitor variants
WO1995023860A2 (en) * 1994-03-04 1995-09-08 Genentech, Inc. KUNITZ DOMAIN INHIBITOR PROTEINS DERIVED FROM ALZHEIMER'S AMYLOID β-PROTEIN PRECURSOR INHIBITOR

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039619A1 (en) * 1995-06-06 1996-12-12 Kla Instruments Corporation Optical inspection of a specimen using multi-channel responses from the specimen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393431A1 (en) * 1989-04-18 1990-10-24 Bayer Ag Homologues of Alzheimer protease inhibitor prepared genetechnologically, host-strains and expression vectors for their preparation and use as a medicament
WO1993014120A1 (en) * 1992-01-07 1993-07-22 Novo Nordisk A/S A human kunitz-type protease inhibitor variant
WO1993014119A1 (en) * 1992-01-07 1993-07-22 Novo Nordisk A/S Human kunitz-type protease inhibitor variants
WO1995023860A2 (en) * 1994-03-04 1995-09-08 Genentech, Inc. KUNITZ DOMAIN INHIBITOR PROTEINS DERIVED FROM ALZHEIMER'S AMYLOID β-PROTEIN PRECURSOR INHIBITOR

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DENNIS M S ET AL: "Kunitz domain inhibitors of tissue factor-factor VIIa: I. Potent inhibitors selected from libraries by phage display.", JOURNAL OF BIOLOGICAL CHEMISTRY 269 (35). 1994. 22129-22136. ISSN: 0021-9258, XP002015893 *
DENNIS M S ET AL: "Kunitz domain inhibitors of tissue factor-factor VIIa: II. Potent and specific inhibitors by competitive phage selection.", JOURNAL OF BIOLOGICAL CHEMISTRY 269 (35). 1994. 22137-22144. ISSN: 0021-9258, XP002015892 *
DENNIS M S ET AL: "Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display.", JOURNAL OF BIOLOGICAL CHEMISTRY 270 (43). 1995. 25411-25417. ISSN: 0021-9258, XP002015896 *
HYNES T R ET AL: "X-RAY CRYSTAL STRUCTURE OF THE PROTEASE INHIBITOR DOMAIN OF ALZHEIMER 'S AMYLOID BETA-PROTEIN PRECURSOR.", BIOCHEMISTRY 29 (43). 1990. 10018-10022. CODEN: BICHAW ISSN: 0006-2960, XP002015891 *
J. PERONA ET AL: "Crystal structures of rat anionic trypsin complexed with the protein inhibitors APPI and BPTI", JOURNAL OF MOLECULAR BIOLOGY, vol. 230, 1993, pages 919 - 933, XP000608106 *
KIDO H ET AL: "PROTEASE-SPECIFICITY OF KUNITZ INHIBITOR DOMAIN OF ALZHEIMER 'S DISEASE AMYLOID PROTEIN PRECURSOR.", BIOCHEM BIOPHYS RES COMMUN 167 (2). 1990. 716-721. CODEN: BBRCA9 ISSN: 0006-291X, XP002015895 *
S. SINHA ET AL: "Conversion of the Alzheimer's beta-Amyloid precursor protein (APP) Kunitz domain into a potent human neutrophil elastase inhibitor", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 31, 5 November 1991 (1991-11-05), MD US, pages 21011 - 21013, XP002015894 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof

Also Published As

Publication number Publication date
WO1996035788A2 (en) 1996-11-14
KR19990008458A (en) 1999-01-25
CA2220497A1 (en) 1996-11-14
JPH11504938A (en) 1999-05-11
AU5854096A (en) 1996-11-29
EP0827539A2 (en) 1998-03-11

Similar Documents

Publication Publication Date Title
WO1996035788A3 (en) Kunitz type protease inhibitors
DE59007737D1 (en) Proteinase inhibitors, processes for their preparation and medicaments containing them.
TR199902692T2 (en) Serine protease inhibitors.
CA2058935A1 (en) Pharmaceutical compositions and method for treatment using alzheimer's amyloid peptides
CA2421548A1 (en) Amidine inhibitors of serine proteases
WO2003066824A3 (en) Albumin-fused kunitz domain peptides
NO20013462L (en) serine protease inhibitors
SE0201976D0 (en) Novel compounds
BR9713328A (en) Aminoguanidines and alkoxyguidines as protease inhibitors.
NO983688L (en) Serine protease inhibitors
SE9602263D0 (en) New amino acid derivatives
WO1999063090A3 (en) Protease inhibitor peptides
AU639257B2 (en) Proteins having anticoagulant properties
Flight et al. Comparison of textilinin-1 with aprotinin as serine protease inhibitors and as antifibrinolytic agents
WO2004113278A3 (en) Acylsulfamide inhibitors of factor viia
NZ319474A (en) Guanidino protease inhibitors
DK0833848T3 (en) Factor IX binding peptides derived from factor VIII and its use as inhibitors of blood coagulation
Schoenberger et al. Limited proteolysis of Cl‐inhibitor by chymotrypsin‐like proteinases
Sulikowski et al. α1‐Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1
JP2839825B2 (en) Novel trypsin-like enzyme
Sugawara et al. Human α-and γ-thrombin inhibition by trypsin inhibitors supports predictions from molecular graphics experiments
Schmaier Gene expression, regulation and cell surface presentation of the kininogens
Steinbuch Regulation of protease activity
BR0212122A (en) Peptide Arginals and Methods for Treatment of Disseminated Intravascular Coagulation
Kobayashi et al. Urinary trypsin-inhibitor protects neutrophil chemotaxis in the inflammatory response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2220497

Country of ref document: CA

Ref country code: CA

Ref document number: 2220497

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019970707988

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 534170

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996920140

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996920140

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970707988

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019970707988

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996920140

Country of ref document: EP